neutralizing antibodies
Showing 26 - 50 of 5,795
HIV, AIDS, Immunologic Deficiency Syndrome, Acquired Trial in Boston (Ad26.Mos4.HIV, MVA-BN-HIV, PGT121)
Recruiting
- HIV
- +4 more
- Ad26.Mos4.HIV
- +4 more
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Apr 18, 2022
Antibacterial Antibodies in Patients With Cystic Fibrosis
Recruiting
- Pulmonary Cystic Fibrosis
- Neutralizing Antibodies
- Blood sampling
-
Cologne, GermanyCF Study Center, University Hospital Cologne
Jan 6, 2021
COVID-19 : Neutralizing Human Monoclonal Antibodies Against
Completed
- COVID
- Blood sample
-
Lyon, FranceHôpital de la Croix-Rousse
Jun 17, 2021
SARS-CoV2, COVID-19 Trial in Antwerpen, Hasselt (Assessing antibody responses, neutralizing capacity and memory B-cell function)
Active, not recruiting
- SARS-CoV2
- COVID-19
- Assessing antibody responses, neutralizing capacity and memory B-cell function
-
Antwerpen, Belgium
- +1 more
Dec 7, 2021
Covid19 Trial (serology)
Unknown status
- Covid19
- serology
- (no location specified)
Sep 11, 2020
Immunological Characteristics of COVID-19 Patients
Recruiting
- Covid19
-
Golnik, SloveniaUniversity Clinic of Respiratory and Allergic Diseases Golnik
Dec 21, 2020
SARS COV-2 IgG Levels on Health Workers Trial in Adana (Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2)
Completed
- SARS COV-2 IgG Levels on Health Workers
- Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
-
Adana, TurkeyAdana Dr. Turgut Noyan Application and Research Center
Apr 13, 2021
Hiv, HIV/AIDS, HIV Trial in San Francisco, Boston, Minneapolis (N-803 and bNAbs, haNK™ Cells)
Withdrawn
- Hiv
- +5 more
- N-803 and bNAbs
- haNK™ Cells
-
San Francisco, California
- +2 more
Oct 21, 2020
HIV-1 Infection Trial in United States (Oral Lenacapavir, Subcutaneous Lenacapavir, Teropavimab)
Active, not recruiting
- HIV-1 Infection
- Oral Lenacapavir
- +3 more
-
Los Angeles, California
- +22 more
Nov 4, 2022
COVID-19, SARS-CoV-2 Trial in Worldwide (AZD5156, Placebo, AZD7442 (EVUSHELD™))
Recruiting
- COVID-19, SARS-CoV-2
- AZD5156
- +2 more
-
Buenos Aires, Argentina
- +20 more
Jan 12, 2023
Dengue Trial in Mexico city (Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high
Not yet recruiting
- Dengue
- Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue
-
Mexico city, MexicoMexican Society of Public Health
Mar 2, 2022
HIV-1-infection Trial in Worldwide (3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J)
Unknown status
- HIV-1-infection
- 3BNC117-LS-J
- +6 more
-
Boston, Massachusetts
- +8 more
Dec 11, 2020
Acute HIV Infection Trial in Brazil, Peru, United States (biological, other, drug)
Not yet recruiting
- Acute HIV Infection
- VRC07-523LS
- +3 more
-
Birmingham, Alabama
- +35 more
Jan 30, 2023
Preexisting Immunity to AAV in Adults With Severe Hemophilia
Completed
- Hemophilia A
- Hemophilia B
- Non-treatment, seroprevalence
-
Los Angeles, California
- +22 more
Oct 22, 2021
COVID-19 Infection in Hospitalized Patients
Unknown status
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection)
- +2 more
- Testing procedure for Binding antibodies
- Neutralizing antibodies
-
Dammam, Eastern, Saudi ArabiaImam Abdulrahman Bin Faisal University
Aug 19, 2020
Use of nMoABs for the Treatment of COVID-19 in Patients With HM.
Completed
- Covid19
- Hematological Malignancy
-
Bari, Italy
- +13 more
Jun 21, 2022
COVID-19 Trial in New Taipei City (Covid19 Vaccination dose)
Recruiting
- COVID-19
- Covid19 Vaccination dose
-
New Taipei City, TaiwanTuCheng Hospital
Apr 24, 2023
Hand, Foot and Mouth Disease Trial (EV71 Vaccine)
Not yet recruiting
- Hand, Foot and Mouth Disease
- EV71 Vaccine
- (no location specified)
Nov 17, 2023
Human Papilloma Virus Infection Trial in Nanjing (Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus
Completed
- Human Papilloma Virus Infection
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
- Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)
-
Nanjing, Jiangsu, ChinaCDC, Jiangsu Province
Jan 12, 2023
Rotavirus Infections, Diarrhea Trial (IRV on a 0- and 28-day schedule, IRV on a 0-, 28- and 56-day schedule, Placebo on Day 0,
Not yet recruiting
- Rotavirus Infections
- Diarrhea
- IRV on a 0- and 28-day schedule
- +3 more
- (no location specified)
Oct 8, 2023
After SARS CoV2 Vaccination in Kidney Transplant Recipients
Recruiting
- Kidney Transplant Recipients
- Study of the synthesis of antibodies directed against SARS
-
Strasbourg, FranceCaillard Sophie
Aug 18, 2022
SARS-CoV-2, Prevention Trial in Chongqing (MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray, Placebo Comparator: MY-586
Recruiting
- SARS-CoV-2
- Prevention
- MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray
- Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient
-
Chongqing, Chongqing, ChinaThe Second Affiliated Hospital of Chongqing Medical University
Aug 2, 2023